Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Nanjing Medical UniversityActive in the last 2 years

Xingxing Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6164-8738; OpenAlex author ID A5100661811. Sources: OpenAlex.

Their work

Papers
3 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 3

  1. Ph-triazole as a therapeutic agent for pancreatic cancer: Synthesis, in silico, and in vitro evaluation. First author DOI 10.1371/journal.pone.0334618↗
  2. Long Intergenic Nonprotein Coding RNA 173 Inhibits Tumor Growth and Promotes Apoptosis by Repressing Sphingosine Kinase 1 Protein Expression in Pancreatic Canc… First author DOI 10.1089/dna.2020.6103↗
  3. Comparative peptidome profiling reveals critical roles for peptides in the pathology of pancreatic cancer. Co-author DOI 10.1016/j.biocel.2020.105687↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Li Zhou · 1 shared paper, 2025 · strength 0.30
  2. Ningbo Zhang · 1 shared paper, 2025 · strength 0.30
  3. Zhuyin Qian · 2 shared papers, 2020–2021 · strength 0.24
  4. Yuqing Gu · 2 shared papers, 2020–2021 · strength 0.24
  5. Qian Li · 1 shared paper, 2021 · strength 0.13
  6. Bin Zhang · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.